The effects of melatonin administration on carotid intima-media thickness and pulse wave velocity in diabetic nephropathy: A randomized, double-blind, placebo-controlled trial

• Published in: Clinical nutrition ESPEN 2022-04, Vol.48, p.82-86
• Main Authors: Talari, Hamid Reza, Tabatabaei, Seyed Mohammad Hossein, Soleimani, Alireza, Sayyah, Mansour, Bozorgi, Maryam
• Format: Article
• Language: English
• Subjects: Carotid Arteries - diagnostic imaging; Carotid Intima-Media Thickness; Diabetes Mellitus; Diabetic Nephropathies - drug therapy; Diabetic nephropathy; Humans; Melatonin - pharmacology; Melatonin supplementation; Pulse Wave Analysis
• ISSN: 2405-4577; 2405-4577
• DOI: 10.1016/j.clnesp.2022.01.002

Previous studies have reported that melatonin intake is inversely associated with reduced markers of atherosclerosis development such as carotid intima-media thickness (CIMT). This study was designed to assess the effects of melatonin administration on CIMT and pulse wave velocity (PWV) in patients with diabetic nephropathy (DN). This randomized, double-blind, placebo-controlled trial was conducted on 32 DN patients. Subjects were assigned to receive melatonin or placebo (starch) for 24 weeks. Individuals in the melatonin group (n = 19) received 10 mg/day. CIMT and PWV levels were taken at the study baseline and after 24 weeks of intervention. After 24 weeks of intervention, melatonin intake did not affect mean levels of left (P = 0.51) and right (P = 0.16) CIMT and maximum levels of left (P = 0.76) and right (P = 0.15) CIMT, and PWV (P = 0.55) compared with the placebo. In addition, within-group difference demonstrated a significant reduction in mean levels of right CIMT (P = 0.01) in the melatonin group. We did not observe any significant change in C-reactive protein (CRP) concentrations after melatonin intake (P = 0.81). Melatonin intake did not affect mean levels of left and right CIMT and maximum levels of left and right CIMT, PWV, CRP levels compared with the placebo. In addition, within-group difference demonstrated a significant reduction in mean levels of right CIMT in the melatonin group. This trial was registered at www.irct.ir as http://www.irct.ir: IRCT20200527047584N2.